Acute myeloid leukaemia secondary to myelodysplastic syndrome
Publication Date: June 2009
ICD 10 AM Edition: Sixth edition
Retired Date: 30/6/2015
Query Number: 2380
Coding a patient who has Acute Myeloid Leukaemia (AML) documented as secondary to myelodysplastic syndrome. Index look up leads to C92.0- and M9871/3 but index also leads to same code under AML without prior MDS, which would appear to be an index error:
Leukaemia:
-myeloid (M9860/3) C92.9-
--acute NOS (M9861/3) C92.0-
---with
----abnormal marrow eosinophils (M9871/3) C92.0-
----maturation (M9874/3) C92.0-
----multilineage dysplasia (M9895/3) C92.0-
----prior myelodysplastic syndrome (M9895/3) C92.0- *
---without
----maturation (M9873/3) C92.0-
----prior myelodysplastic syndrome (M9895/3) C92.0- *
Leukaemia:
-myeloid (M9860/3) C92.9-
--acute NOS (M9861/3) C92.0-
---with
----abnormal marrow eosinophils (M9871/3) C92.0-
----maturation (M9874/3) C92.0-
----multilineage dysplasia (M9895/3) C92.0-
----prior myelodysplastic syndrome (M9895/3) C92.0- *
---without
----maturation (M9873/3) C92.0-
----prior myelodysplastic syndrome (M9895/3) C92.0- *
Response
The VICC referred this query to the NCCH who provided the following advice:
“In Third Edition revisions were made to ICD-10-AM which incorporated codes from WHO's International Classification of Diseases for Oncology (ICD-O), Third Edition. This classification formed the basis of the index pathways cited in your query.
The NCCH acknowledges that AML with myelodysplastic syndrome and AML without myelodysplastic syndrome are clinically different, however, the classification groups them together.
Suggestions for changes to the morphology codes should be lodged as a formal suggestion to AIHWs National Cancer Statistics Clearing House (NCSCH).”
“In Third Edition revisions were made to ICD-10-AM which incorporated codes from WHO's International Classification of Diseases for Oncology (ICD-O), Third Edition. This classification formed the basis of the index pathways cited in your query.
The NCCH acknowledges that AML with myelodysplastic syndrome and AML without myelodysplastic syndrome are clinically different, however, the classification groups them together.
Suggestions for changes to the morphology codes should be lodged as a formal suggestion to AIHWs National Cancer Statistics Clearing House (NCSCH).”